2010 Scrip 100 - Japan therapeutic NME and new biological approvals
This article was originally published in Scrip
Executive Summary
Japan therapeutic NME and new biological approvals*
Product
Generic name
Company
Indication
Month of approval
Adoair
salmeterol plus fluticasone
GlaxoSmithKline
asthma
January 2009
Apidra
insulin glulisine
Sanofi-Aventis
diabetes
April 2009
Asmanex
mometasone
Schering-Plough
asthma
July 2009
Avolve
dutasteride
GlaxoSmithKline
benign prostatic hyperplasia
July 2009
BeneFIX
nonacog alfa
Wyeth/Pfizer
haemophilia
October 2009
Celsentri
maraviroc
Pfizer
HIV
December 2008
Clozaril
clozapine
Novartis
schizophrenia
April 2009
Emend
aprepitant
Ono
nausea and vomiting
October 2009
Intelence
etravirine
Janssen
HIV
December 2008
Januvia/Glactiv
sitagliptin
Merck & Co/Ono
diabetes
October 2009
Lucentis
ranibizumab
Novartis
wet AMD
January 2009
Lumigan
bimatoprost
Senju
glaucoma/ocular hypertension
July 2009
Miripla
miriplatin
Dainippon Sumitomo
liver cancer
October 2009
Orapenem
debipenem
Meiji Seika
infections
April 2009
Rasilez
aliskiren
Novartis
hypertension
July 2009
Rasuritek
rasburicase
Sanofi-Aventis
hyperuricaemia
October 2009
Remeron/Reflex
mirtazapine
Schering-Plough/Meiji Seika
depression
July 2009
Remitch
nalfurafine
Toray
pruritus
January 2009
Recalbon/Bonoteo
minodronate
Ono/Astellas
osteoporosis
January 2009
Sprycel
dasatinib
Bristol-Myers Squibb
leukaemia
January 2009
Strattera
atomoxetine
Lilly
paediatric ADHD
April 2009
Symbicort
budesonide plus formoterol
AstraZeneca
asthma
October 2009
Tasigna
nilotinib
Novartis
leukaemia
January 2009
Trerief
zonisamide
Dainippon Sumitomo
Parkinson's disease
January 2009
Tykerb
lapatinib
GlaxoSmithKline
breast cancer
April 2009
Xolair
omalizumab
Novartis
asthma
January 2009
Vaccines
Cervarix
GlaxoSmithKline
HPV prophylaxis
October 2009
Prevenar
Wyeth/Pfizer
pneumococcal prophylaxis
October 2009
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.